Vitamin B12 deficiencyBMJ 2014; 349 doi: https://doi.org/10.1136/bmj.g5226 (Published 04 September 2014) Cite this as: BMJ 2014;349:g5226
- Alesia Hunt, haematology specialist registrar,
- Dominic Harrington, consultant clinical scientist, and scientific director of Viapath LLP,
- Susan Robinson, haematology consultant
- Correspondence to: A Hunt
Vitamin B12 deficiency is a common but serious condition
Clinical presentation may not be obvious thus leading to complex issues around diagnosis and treatment
There is no ideal test to define deficiency and therefore the clinical condition of patients is of the utmost importance
There is evidence that new techniques such as the measurement of holotranscobalamin and methylmalonic acid levels seem useful in more accurately defining deficiency
If the clinical features suggest deficiency then it is important to treat patients to avoid neurological impairment even if there may be discordance between the results and clinical features
Vitamin B12 is an essential cofactor that is integral to methylation processes important in reactions related to DNA and cell metabolism, thus a deficiency may lead to disruption of DNA and cell metabolism and thus have serious clinical consequences.1 Intracellular conversion of vitamin B12 to two active coenzymes, adenosylcobalamin in mitochondria and methylcobalamin in the cytoplasm, is necessary for the homeostasis of methylmalonic acid and homocysteine, respectively.2 3 Methylmalonic acid is converted into succinyl-CoA, of which vitamin B12 is a cofactor for the reaction. Homocysteine is biosynthesised from methionine then resynthesised into methionine or converted into amino acid cysteine.
Vitamin B12 (also referred to as cobalamin) deficiency is relatively common, with important and variable clinical consequences. This review presents a concise summary of the most up to date evidence on how to diagnose and manage vitamin B12 deficiency.
Sources and selection criteria
We searched PubMed and Google Scholar using the terms “vitamin B12 deficiency” and “cobalamin deficiency”, and hand selected the most relevant and appropriate articles. We also used evidence based guidelines from the British Committee for Standards in Haematology; however, evidence, especially in the form of randomised controlled trials, is lacking.4
What causes vitamin B12 deficiency?
Foods containing vitamin B12 are derived only from animals: meat, fish, and dairy. The daily Western diet contains around 5-30 µg of vitamin B12 daily, of which 1-5 µg is absorbed. The UK government recommends a daily intake of 1.5 µg of vitamin B12, with the European Union recommending 1 µg and the United States recommending 2.4 µg. Body storage is relatively high, about 1-5 mg. Therefore deficiency from diminished intake or absorption may not manifest for several years after the depletion of stores.1 5 6 Box 1 outlines the common causes of vitamin B12 deficiency.
Impaired gastric absorption
Gastrectomy—partial or total
Impaired intestinal absorption
Ileal resection or disease—for example, Crohn’s inflammatory bowel disease and tuberculous ileitis
Blind loop syndrome
Luminal disturbances: chronic pancreatic disease and gastrinoma
Parasites: giardiasis, bacterial overgrowth, and fish tapeworm
Reduced intake of animal products
Strict vegan diet
Intrinsic factor receptor deficiency/defect—Imerslund-Gräsback syndrome
Congenital deficiency of intrinsic factor—“juvenile” pernicious anaemia
Cobalamin mutation (C-G-1 gene)
Proton pump inhibitors
H2 receptor antagonists
Slow K (potassium chloride) preparations
Who gets vitamin B12 deficiency and how common is it?
Deficiency can manifest in different groups as a result of periods when requirements are increased, such as during growth in children and adolescence or in pregnancy. Certain groups may have reduced intake, such as those with poor nutrition, older people, or people who adhere to a vegan or vegetarian diet.
In the United Kingdom and United States the prevalence of vitamin B12 deficiency is around 6% in people aged less than 60 years, and closer to 20% in those aged more than 60 years. Across Latin America approximately 40% of children and adults have clinical or subclinical deficiency. The prevalence of deficiency is much higher in African and Asian countries—for example, 70% in Kenyan schoolchildren, 80% in Indian preschool children, and 70% in Indian adults.10 In vegan and vegetarian groups the rates vary—in the United Kingdom, 11% of vegans are deficient in vitamin B12 and in Ethiopia 62% of vegetarian pregnant women are deficient.11
What is the pathophysiology of vitamin B12 deficiency?
In serum, vitamin B12 is bound to haptocorrin as holohaptocorrin (formally transcobalamin III) and to transcobalamin as holotranscobalamin. Holohaptocorrin accounts for 80-94% of endogenous plasma vitamin B12. Holotranscobalamin on the other hand accounts for 6-20% of bound vitamin B12. It is synthesised in enterocytes and, through receptor mediated endocytosis, is responsible for uptake of vitamin B12 from the ileum into the blood as well as into other cells. Only vitamin B12 bound as holotranscobalamin is presented for cellular uptake. The malabsorption of this holotranscobalamin protein-bound vitamin B12 results in vitamin B12 deficiency in several cases.12
Intrinsic factor is a protein, produced by the parietal cells of the cardiac and fundic mucosa of the stomach. It binds vitamin B12 to allow its absorption through the gastrointestinal tract, by way of a receptor on the intrinsic factor that is specific to cells at the terminal ileum. If there is resection or disease of the gastric mucosa or terminal ileum this leads to vitamin B12 deficiency as a result of malabsorption.
Pernicious anaemia is an autoimmune disease with atrophy of the gastric mucosa of the body and fundus of the stomach. This reduces the number of parietal cells that produce the intrinsic factor necessary for absorption of vitamin B12. Secretion of intrinsic factor parallels gastric acid; thus there will be reduced secretion in an alkaline environment created by the long term use of high dose proton pump inhibitors and similar drugs. Figure 1⇓ illustrates the normal mechanism of vitamin B12 absorption.
What are the clinical features of vitamin B12 deficiency?
The clinical manifestations of vitamin B12 deficiency (fig 2⇓),3 5 6 7 9 13 represent the effects of depletion on multiple systems and vary greatly in severity. The clinical manifestations are heterogeneous but can also be different depending on the degree and duration of deficiency.
Mild deficiency manifests as fatigue and anaemia, with indices suggesting B12 deficiency but an absence of neurological features. Moderate deficiency may include an obvious macrocytic anaemia with, for example, glossitis and some mild or subtle neurological features, such as distal sensory impairment. Severe deficiency shows evidence of bone marrow suppression, clear evidence of neurological features, and risk of cardiomyopathy. However, it is important to recognise that clinical features of deficiency can manifest without anaemia and also without low serum vitamin B12 levels. In these cases treatment should still be given without delay.4 13
The bone marrow is most commonly affected. Anaemia may range from mild to severe, with symptoms of fatigue on exertion, dyspnoea, palpitations, and pallor. All cell lines can be affected, with macrocytic anaemia, low white cell count or neutropenia, and thrombocytopenia.
Tissues and organ dysfunction
Epithelial changes with vitamin B12 deficiency include skin hyperpigmentation and glossitis. Reproductive tissue can be affected, manifesting as infertility. Deficiency can also result in osteoporosis, with reduced bone derived alkaline phosphatase and plasma osteocalcin. Rarely, cardiomyopathy can occur.3
Neurological impairment includes motor disturbances, sensory loss, abnormal balance and reflexes, cognitive impairment, and memory loss. Extreme cases may present with stupor or psychosis. An estimated 20% of patients with neurological signs do not manifest anaemia.13 Clinical features of anaemia may be minimal and the blood indices may not reflect important anaemia. Neurological symptoms can occur in isolation so it is important to consider a diagnosis of vitamin B12 deficiency in the presence of neurological symptoms of unknown cause, as neurological features may progress and become irreversible.
Subacute combined degeneration of the spinal cord involves demyelination of the posterior and lateral tracts. Initial bilateral peripheral neuropathy can progress to axonal degeneration and neuronal death if left untreated. This is followed by disturbances of proprioception, vibratory sense, and areflexia. Patients may mention clumsiness, poor coordination, and difficulty walking. Without treatment, weakness and stiffness may develop, manifesting as spastic ataxia. Damage to peripheral nerves results in sleepiness, altered taste and smell, and optic atrophy. In severe deficiency or advanced stages, a dementia-like illness may be seen, and frank psychosis with hallucinations, paranoia, and severe depression.9 13
Which investigations should be carried out to determine vitamin B12 deficiency?
Several investigations reflecting physiological, static, and functional B12 status are available (table⇓). Box 2 outlines when testing for vitamin B12 deficiency should be considered.
Box 2 When to consider testing for vitamin B12 deficiency
Macrocytosis mean cell volume >100 fl
Clinical symptoms of vitamin B12 deficiency
Known gastrointestinal disorder associated with vitamin B12 deficiency
There is still no ideal test for measuring vitamin B12 deficiency. Measuring the serum cobalamin level remains the preferred choice. Second line tests include measuring plasma methylmalonic acid levels, which can help clarify uncertainties of underlying biochemical and functional deficiencies. Serum holotranscobalamin has an indeterminate “grey area” and therefore should be correlated with testing for methylmalonic acid. Testing for plasma homocysteine may be helpful but is less specific than for methylmalonic acid.4 Furthermore, given the variety of laboratory techniques and assay, reference ranges are established locally, resulting in an inability of definitive definitions for clinical and subclinical deficiency states.
Investigations that may allude to physiological changes reflecting vitamin B12 deficiency include full blood count (mean cell volume and haemoglobin), reticulocyte count, blood film, and lactate dehydrogenase. Macrocytosis is the most common trigger for checking vitamin B12 status. Bone marrow biopsy is rarely required but may be indicated in selective cases where the diagnosis is unclear or blood indices show that the patient is not responding to adequate treatment (fig 3⇓).
Patients with a concomitant iron deficiency may not develop the morphological features of vitamin B12 deficiency until the iron deficiency has resolved. Macrocytosis may also be absent or masked by thalassaemia trait.5 6 7 The diagnostic algorithim in figure 4⇓ can be used to interpret the results of the full blood count and haematinic tests.
Vitamin B12 level
Vitamin B12 level is actually a measurement of serum cobalamin. Measurement of vitamin B12 in serum is the most common assay used to evaluate vitamin B12 levels. The test, however, also measures both serum holohaptocorrin and serum holotranscobalamin, and as such may mask true deficiency or falsely imply a deficient state. The test is widely available at low cost and uses an automated method and competitive-binding immune chemiluminescence.2 4 14 15 16 17
The clinically normal level for serum cobalamin is not completely clear. It has been suggested that serum cobalamin <148 pmol/L (200 ng/L) would be sensitive enough to diagnose 97% of patients with vitamin B12 deficiency. It is not clear what level of serum cobalamin may represent subclinical deficiency.4
Holotranscobalamin, the metabolically active form of vitamin B12, can be measured by immunoassay. Reference ranges depend on the individual assay, according to the specific laboratory. The theoretical merits of measuring the levels of holotranscobalamin have been known for many years but it is only recently that an assay suited to routine use, known as active B12, has become available. Emerging evidence indicates that a low level of holotranscobalamin is a more reliable marker of impaired vitamin B12 status than is a low level of serum vitamin B12.17 Holotranscobalamin may be the earliest marker for vitamin B12 depletion. This test is increasingly being adopted; however, discrepancies remain about mode of application and assignment of cut-off values. A second confirmatory test, such as for methylmalonic acid levels, is recommended if the result is in the intermediate range.18
The conversion of methylmalonic acid to succinyl-CoA requires B12 as a cofactor and hence accumulation occurs if B12 is not available. An increase in methylmalonic acid level is an indicator of vitamin B12 deficiency in tissue and this persists for several days even after replacement is started.2 Measurement of methylmalonic acid may be the most representative marker of metabolic vitamin B12 insufficiency. The interpretation in older patients (>65 years) and those with impaired renal function is, however, potentially challenging because levels can be falsely increased. High levels of plasma methylmalonic acid, however, usually indicate cobalamin deficiency. Methylmalonic acid is measured using gas chromatography mass spectrometry, a high cost test.
Plasma total homocysteine levels are increased in B12 deficiency. Plasma total homocysteine can increase early in the course of deficiency. It is a sensitive but non-specific marker and it is also high in folate deficiency, B6 deficiency, renal failure, and hypothyroidism. Most laboratories regard levels >15 µmol/L as high, although the reference range depends on the individual technique. The sample must be processed within two hours, which may inhibit the usefulness of the test.
Identifying the cause of vitamin B12 deficiency
Once a diagnosis of vitamin B12 deficiency is identified, history taking and examination are important (see fig 3). If there is no obvious dietary lack of vitamin B12 or malabsorption, tests for intrinsic factor and antiparietal cell antibodies should be performed to exclude pernicious anaemia.19
How is vitamin B12 deficiency treated?
Timing of treatment
It is usually acceptable to start treatment within a few days of a confirmed diagnosis (box 3 summarises treatment and management). If there are neurological disturbances then treatment should be expedited and started without delay. Specialist input should be sought in the event of neurological features, including impaired cognitive state (box 4). Neurological presentation may occur in the absence of haematological changes, with early treatment essential to avoid permanent neurological disability. Emergency treatment with packed red cell transfusion may be required for major anaemia in the presence of cardiovascular compromise.24
Box 3 Summary of treatment and management of vitamin B12 deficiency
Identify and treat the cause
Administer hydroxycobalamin (parenteral vitamin B12) 1 mg intramuscularly on alternate days for two weeks if there is no neurological involvement
Start folic acid 5 mg daily after B12 supplementation
Provide supportive care; including, if required, rest, oxygen, red cell transfusion
Monitor and treat hypokalaemia, which can occur with B12 treatment
Prescribe lifelong maintenance parenteral vitamin B12 treatment with hydroxycobalamin 1 mg intramuscularly every three months if no neurological deficit, or every two months if there is neurological deficit to all those with irreversible malabsorption or after gastric surgery, pernicious anaemia, and any other irreversible cause
Follow up long term, especially for treatment of the cause
Educate patients and families, especially when parenteral lifelong treatment is needed in pernicious anaemia
Consider concomitant deficiencies if diet is poor, and treat as required
Refer to specialist if required (box 4)
Box 4 Who to refer for specialist care23
Referrals to haematologist
If diagnosis is uncertain or unclear
If the cause of B12 deficiency is unclear
If response to treatment is inadequate
If the patient is pregnant or neurological symptoms are present, including cognitive impairment
If the suspected cause is haematological malignancy or another blood disorder
If the mean cell volume is persistently >105 fL
Referrals to gastroenterologist
For malabsorption or inflammatory bowel disorder as required
Suspected gastric malignancy with anaemia secondary to gastrointestinal blood loss should be referred appropriately through the “urgent two week referral” and not a routine haematology referral
Data from randomised controlled trials and observational studies for parenteral treatment are lacking; however, the expert consensus for standard treatment in the United Kingdom is to begin parenteral treatment with intramuscular hydroxocobalamin. This bypasses the possibility of the debate about whether the treatment will be adequately taken, absorbed, and metabolised. Standard initial treatment for patients without neurological involvement is 1000 µg intramuscularly three times a week for two weeks. If there are neurological symptoms then 1000 µg intramuscularly on alternate days should be continued for up to three weeks or until there is no further improvement.4 25 In irreversible cases, for example, pernicious anaemia, the treatment should be continued for life. For temporary causes, such as pregnancy, the treatment can be reviewed when the patient is fully replete and the causative agent removed.
Hydroxocobalamin is generally well tolerated. Rarely, side effects include itching, exanthema, chills, fever, hot flushes, nausea, dizziness, and very rarely anaphylaxis. There can be a cross over reaction to cobalamin; if there is concern about this then the drug should be administered in a place where hypersensitivity can be managed, with hydrocortisone and chlorphenamine cover available.4 26 27
Cyanocobalamin is an oral preparation that can be given at a dose of 50-150 µg daily, as licensed and outlined in the British National Formulary.25 The duration is determined by the cause of the deficiency. If the cause is irreversible then parental therapy should be continued for life. This is a drug preparation requiring conversion to metabolically active cobalamins. A Cochrane review of two randomised controlled trials in 108 people with vitamin B12 deficiency found that high oral doses of B12 (1000 µg and 2000 µg daily) were as effective as intramuscular treatment in achieving haematological and neurological responses.28 However, UK national consensus is that there are arguments against the use of oral cobalamin in severely deficient patients and those with malabsorption. High dose oral cobalamin may be a suitable alternative in selective cases, where intramuscular injections are not tolerated and compliance is not a problem, as previously described.3
Treatment with vitamin B12 leads to the production of new erythrocytes, which results in an intracellular influx of potassium. This may produce severe hypokalemia, which requires monitoring and appropriate treatment.
Treating concomitant deficiencies
If there is concomitant vitamin B12 and folic acid deficiency then vitamin B12 must be started first to avoid precipitating subacute combined degeneration of the spinal cord. In patients with isolated vitamin B12 deficiency and anaemia, additional folic acid supplementation is recommended until vitamin B12 is replete, to prevent subsequent folate deficiency after replenishment of B12 stores.7 12 23 24 Iron deficiency can be treated with oral ferrous sulphate (or suitable alternative) 200 mg three times daily with vitamin C supplementation. If this is not tolerated or effective then referral to a specialist may be required.
How is response to treatment assessed?
Patients often have a sense of improvement within the first 24 hours of treatment; however, the haematological response can take several days before the effects are first noticed and up to two months to complete response.3
Initially, a full blood count and reticulocyte count after 7-10 days of treatment is useful to document the response, and a further check should be done after eight weeks to confirm a normal blood count. When there is inadequate reticulocytosis, an incorrect diagnosis may be responsible. Within eight weeks of treatment the mean cell volume should have normalised (77-95 fL). Iron and folate status should be checked because coexisting deficiency is often obscured in vitamin B12 deficiency.22 29
Homocysteine or methylmalonic acid should normalise during the first week of treatment. Failure to do so suggests an incorrect diagnosis, unless renal failure or other causes of increases in the metabolites coexist. Cobalamin and holotranscobalamin levels are not helpful because they increase with vitamin B12 influx regardless of the effectiveness of treatment,24 and retesting is not usually required. They can be tested 1-2 months after starting treatment or if there is no response to treatment.
Neurological recovery may take some time; improvement begins within one week and complete resolution usually occurs between six weeks and three months. Progression should prompt reassessment of the diagnosis. Patients with delayed improvement should be referred for rehabilitation, including physiotherapy. Residual disability is seen in up to 6% of patients. Damage is likely to be irreversible if diagnosis and treatment are delayed by six months.3 24
Recent advances and future developments
One study successfully identified the plasma protein that binds transcobalamin saturated with vitamin B12. Further investigation into the genetic variability of this transcobalamin receptor and its interaction with transcobalamin polymorphisms may yield useful insights into variable responses to treatment.30
Can vitamin B12 deficiency be prevented?
It is not currently possible to prevent vitamin B12 deficiency from pernicious anaemia. Deficiency due to gastric and terminal ileum disease should be anticipated and supplemented before clinical presentation of deficiency. Breakfast cereals are fortified with vitamin B12, as a non-animal based dietary source. This may be useful for older people (>65 years) and those with a restricted diet. Each portion contains approximately 25% of the recommended daily intake of vitamin B12.31 For patients taking long term metformin and proton pump inhibitors the use of oral cyanocobalamin could be considered, or increased screening and vigilance of vitamin B12 deficiency.9
Additional educational resources
Information for healthcare professionals
National Institute for Health and Care Excellence. Clinical knowledge summaries. Anaemia–B12 and folate (http://cks.nice.org.uk/anaemia-b12-and-folate-deficiency)—provides a clear overview of the topic, which is easily navigated
Patient.co.uk. Pernicious anaemia and B12 deficiency (www.patient.co.uk/doctor/pernicious-anaemia-and-b12-deficiency)—an easy to understand overview with ability to print the literature in PDF format and with links to related issues
British Committee for Standards in Haematology. Haematology guidelines (www.bcshguidelines.com/4_haematology_guidelines.html)—guidelines for the diagnosis and treatment of cobalamin and folate disorders
Information for patients
NHS Direct Wales (www.nhsdirect.wales.nhs.uk/encyclopaedia/ch/article/anaemia,vitaminb12andfolatedeficency/)—a clear concise overview of vitamin B12 deficiency with some related links
NHS Choices. Vitamin B12 or folate deficiency anaemia. (www.nhs.uk/conditions/anaemia-vitamin-B12-and-folate-deficiency/Pages/introduction.aspx)—a clear overview, with access to patient forums
Patient.co.uk. Vitamin B12 deficiency anaemia (www.patient.co.uk/health/vitamin-b12-deficiency-and-pernicious-anaemia)—contains information similar to that provided by doctors during consultations
Pernicious Anaemia Society (www.pernicious-anaemia-society.org)—a charitable organisation based in the United Kingdom and providing a support forum for people with pernicious anaemia worldwide
Cite this as: BMJ 2014;349:g5226
We thank Renata Gorska (Guy’s and St Thomas’ NHS Foundation Trust) for assistance with figure 1 and Alison Thomas and Deepti Radia (Guy’s and St Thomas’ NHS Foundation Trust) for supplying the morphology pictures.
Competing interests: We have read and understood the BMJ Group policy on declaration of interests and declare the following: DH has received travel expenses from Axis Shield Diagnostics and honorariums for lectures from Abbott Diagnostics. DH’s position as scientific director for Viapath LLP is not associated with board membership or financial interests.
Provenance and peer review: Commissioned; externally peer reviewed.